S. Ikehara was the first to develop the use of bone marrow transplantation (BMT) in the treatment of severe autoimmunity, with works published as early as 1985. He also discovered that adoptive transfer of partially purified hematopoietic stem cells from autoimmune-prone mice could lead, following transplantation, to the appearance of autoimmunity in normal mouse recipients. These early observations gave way to studies on improved methods for not only isolation of stromal cells, including mesenchymal stem cells (MSCs), but also the characterization of ideal conditions for successful allogeneic BMT. Professor Ikehara’s early work has now become standard in laboratories throughout the world and has formed the basis for the treatment of patients who have failed on conventional therapies for scleroderma, Crohn’s disease, and a variety of other pathologies. He received his M.D. (1968) and his Ph.D. degrees (1977) from Kyoto University, Kyoto, Japan. He began his career in the Department of Pathology at Kyoto University (1976) and was promoted to Professor of pathology within the Department of Immunology at Kansai Medical University, Moriguchi, Japan, (1986). He has served as the Director of the Transplantation Center at Kansai Medical University since 1998 as well as Director of the Regeneration Research Center for Intractable Diseases since 2001, and finally as the Director for Cancer Therapy in 2003 at Kansai Medical University. He has been a distinguished Visiting Investigator with Dr. Robert A. Good at Memorial Sloan Kettering Cancer Center in 1978–1981. Professor Ikehara has received numerous awards, including those from the Mitsubishi Foundation, the Takeda Science Foundation, the CIBA-GEIGY Award, and the Clemens von Pirquet Award from the University of California, Davis, Davis, Calif, USA.
Biography Updated on 9 March 2011